Mindstate Design Labs

Clinical-stage AI neuroengineering platform

Y CombinatorSummer 2021ActiveHealthcareDrug Discovery and DeliveryMachine LearningMental Health TechBiotechTherapeutics

What they do

Problem

Current psychiatric and therapeutic drugs cannot reliably and rapidly induce specific beneficial emotional states on demand without unwanted effects like hallucinations.

Solution

An AI neuroengineering platform that models psychoactive pharmacology to design rapid-acting compounds (starting with MSD-001) that elicit targeted therapeutic emotions and cognitive states.

Who it's for

Pharmaceutical and biotechnology companies developing clinical therapeutics for mental health and related indications.

Founders

Dillan DiNardo

Founder/CEO

Creating new classes of psychoactive therapeutics as Founder/CEO at Mindstate Design Labs. Former biotech VC.

LinkedIn · X

Tom Ray

Founder

BS in biology & chemistry Florida State University. MS & PhD in biology Harvard, tropical plant ecology. 1981 Society of Fellows U Michigan Ann Arbor. 1981-1998 faculty University Delaware, biology & computer science. 1993-2003 External Faculty of the Santa Fe Institute. 1993-1998 invited researcher ATR (Advanced Telecommunications Research Institute) Human Information Processing Research Labs in Japan. In 1998-present Professor of Biology & Computer Science OU. AAAS Fellow. http://tomray.me/